文献速递生殖医学

仅用阴道黄体酮(Endometrin)替代的玻璃化囊胚移植周期持续妊娠率较低:三臂随机对照非劣效性试验的计划中期分析结果

Vitrified blastocyst transfer cycles with the use of only vaginal progesterone replacement with Endometrin have inferior ongoing pregnancy rates: results from the planned interim analysis of a three-arm randomized controlled noninferiority trial.
PubMed 文献 · Fertil Steril · 2018-01-17

该三臂随机对照非劣效性试验中期分析纳入645个周期,比较每日肌注黄体酮、单用阴道黄体酮(Endometrin)及阴道黄体酮联合每3天肌注黄体酮三种方案。单用阴道黄体酮组持续妊娠率31%,显著低于另两组,且流产率显著升高;该组随机化已终止。

要点

  • 单用阴道黄体酮组持续妊娠率31%,显著低于含肌注黄体酮的两组(50%和47%)。
  • 单用阴道黄体酮组阳性hCG率与其他两组相当,但流产率显著更高。
  • 每日肌注黄体酮组与阴道联合每3天肌注黄体酮组各结局无显著差异。

核心结论

  • 与含肌注黄体酮的方案相比,仅用阴道黄体酮进行玻璃化囊胚移植替代会导致持续妊娠率降低,原因是流产增加,应避免使用。
  • 单用阴道黄体酮组的随机化已因上述发现而终止;试验仍在进行,以评估阴道黄体酮联合每3天肌注黄体酮组与每日肌注黄体酮组在活产方面的非劣效性。

研究设计与样本

  • 三臂随机对照非劣效性研究,在辅助生殖技术实践中进行。
  • 计划在总入组目标50%的持续妊娠数据可用时进行中期分析,本文报告该中期分析结果。
  • 共645个周期被随机分配至三组,接受至少一剂黄体酮替代治疗并完成玻璃化囊胚移植,纳入意向性分析。
  • 研究团队(包括统计师)对治疗分组设盲,数据集内以「A」「B」「C」随机标注。
  • 主要结局为活产,本中期分析的主要结局为持续妊娠。

主要发现

  • A组、B组和C组的持续妊娠率分别为50%、47%和31%。
  • C组阳性hCG率与另两组相当,但C组流产率显著高于另两组,导致持续妊娠率降低超过三分之一。
  • A组与B组之间任何检测结局均无统计学显著差异。
  • 符合方案分析结果与意向性分析结果几乎一致。
  • 分析完成后揭盲,C组为单用阴道黄体酮组。

关键数值与推荐

  • 干预方案:每日肌注黄体酮50 mg;阴道Endometrin 200 mg每日两次;阴道Endometrin 200 mg每日两次联合每3天肌注黄体酮50 mg。
  • 纳入人群:在程序化周期中接受未活检高质量玻璃化囊胚移植的女性。

临床怎么用

  • 作者结论认为,与含肌注黄体酮的方案相比,仅用阴道黄体酮应避免使用。

局限性

  • 本文报告的是计划中期分析结果,试验仍在进行中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the noninferiority of vaginal P (Endometrin) compared with daily intramuscular P for replacement in programmed vitrified-warmed blastocyst transfer cycles and to assess the noninferiority of vaginal P in combination with intramuscular progesterone every third day compared with daily intramuscular P. DESIGN: Three-arm randomized controlled noninferiority study. To enable early recognition of inferiority if present, an a priori interim analysis was planned and completed once ongoing pregnancy data were available for 50% of the total enrollment goal. The results of this interim analysis are presented here. SETTING: Assisted reproduction technology practice. PATIENT(S): Women undergoing transfer of nonbiopsied high quality vitrified-warmed blastocyst(s) in a programmed cycle. INTERVENTION(S): Vitrified-warmed blastocyst transfer with mode of P replacement determined by randomization to either: (1) 50 mg daily intramuscular P only; (2) 200 mg twice daily vaginal Endometrin; or (3) 200 mg twice daily Endometrin plus 50 mg intramuscular P every 3rd day. MAIN OUTCOME MEASURE(S): Live birth. The primary outcome of this interim analysis was ongoing pregnancy. RESULT(S): A total of 645 cycles were randomly assigned to one of the three treatment arms, received at least one dose of P replacement therapy according to this assignment and underwent vitrified-warmed blastocyst transfer. These cycles were included in the intention-to-treat analysis. The study team, including the statistician, were blinded to the identity of the treatment arms, which were randomly labeled "A," "B," and "C" in the dataset. Ongoing pregnancy occurred in 50%, 47%, and 31% of cycles in arms A, B, and C respectively. Although arm C had an rate of positive hCG equivalent to the other two arms, the rate of pregnancy loss for arm C was significantly higher than for either of the two arms, resulting in a more than one-third lower rate of ongoing pregnancy. There were no statistically significant differences for any outcome tested between arms A and B. Results of a per-protocol analysis were nearly identical to those of the intention-to-treat analysis. On completion of these analyses, arm C was revealed to be the vaginal P only arm. CONCLUSION(S): Relative to regimens inclusive of intramuscular P, vaginal-only P replacement for vitrified-warmed blastocyst transfer results in decreased ongoing pregnancy, due to increased miscarriage, and should be avoided. Randomization to the vaginal-only arm was terminated with these findings. This trial is ongoing to assess the noninferiority of the vaginal plus every 3rd day intramuscular P arm compared with daily intramuscular P in terms of live birth. CLINICAL TRIAL REGISTRATION NUMBER: NLM identifier NCT02254577.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Devine K, Richter KS, Widra EA, et al. Vitrified blastocyst transfer cycles with the use of only vaginal progesterone replacement with Endometrin have inferior ongoing pregnancy rates: results from the planned interim analysis of a three-arm randomized controlled noninferiority trial. Fertil Steril. 2018. PMID: 29338855. doi:10.1016/j.fertnstert.2017.11.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。